New probiotic strains have been discovered due to their increasing popularity in various countries such
as India, Europe, Japan, Brazil, the USA, and Canada, driven by their potential health benefits. Before
incorporating probiotics into food products, thorough safety assessments and reliable clinical trials are
essential. False claims and improper use of "probiotics" weaken consumer trust and inhibit the industry's
growth. There are still challenges in selecting, developing, and utilizing probiotics efficiently. Before
employing probiotics as medication, a thorough study of safety aspects, patient risk assessments, and
appropriate handling practices is essential. The fragmented worldwide regulatory framework confuses
probiotic manufacturers, consumers, regulatory agencies, and scientists. Harmonizing legislation across
different nations is necessary by categorizing probiotics according to their claims. Fighting false health
claims and ensuring reliable information is crucial. Regulating probiotics according to risk (source,
intended use) enables the implementation of suitable measures. Confusion would decrease, and a single
regulatory framework would make safe commercialization easier. Future regulations could establish a
multi-tiered classification system that meets specific standards. We must resolve these issues to
guarantee probiotics' secure and efficient use. Encouraging scientific study, implementing clear
labelling, and aiming for global regulatory harmonization will allow us to realize the total health
benefits of probiotics.
Keywords: Probiotics, Regulatory bodies, Probiotics categorization, LAB, QPS, GMO
Publication date: 01/11/2025
https://ijbpas.com/pdf/2025/November/MS_IJBPAS_2025_9599.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.11.9599
